JAMA Intern Med:5.2%高脂血症患者有甲减,指南建议用药前检查甲功

2019-02-28 xujing 中国循环杂志

甲状腺功能减退是引起高脂血症和相关冠心病的原因。通过治疗明显的甲状腺功能减退可以改善胆固醇水平。

甲状腺功能减退是引起高脂血症和相关冠心病的原因。通过治疗明显的甲状腺功能减退可以改善胆固醇水平。
 
目前指南建议,在开始使用降脂药物前,对新诊断的高脂血症患者检查甲状腺功能。
 
一项纳入8795例高脂血症患者的研究发现,只有大约50%的新诊断的高脂血症患者接受了甲状腺功能不全的筛查(高脂血症诊断后6个月内)。
 
甲状腺功能减退的诊断率为5.2%。151例(3.5%)患者的TSH水平为5~10 mIU/L,74例(1.7%)患者的TSH水平大于10 mIU/L。
 
TSH水平大于10 mIU/L的患者,推荐使用左旋甲状腺素治疗。
 
约50%的TSH水平升高的患者接受左甲状腺素治疗;30%的TSH水平高于10 mIU/L的患者未接受治疗。
 
在接受左甲状腺素治疗的患者中,相当比例(75%)的患者在1年内不需要降脂药物。
 
尽管79%的患者已经矫正了甲状腺功能减退,但60.5%的患者没有再检查血脂水平。重新检查血脂水平的患者中,21例(61.8%)没有了高脂血症。
 
原始出处:Willard DL, et al. Thyroid Function Testing in Patients With Newly Diagnosed Hyperlipidemia. JAMA Intern Med. 2014, 174(2): 287–289.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1341321, encodeId=316d13413210a, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574637, encodeId=672815e4637d5, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609614, encodeId=bff316096147b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361775, encodeId=2a40361e7527, content=我们的病人严重血脂异常的都查甲功, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Fri Mar 01 11:01:13 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1341321, encodeId=316d13413210a, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574637, encodeId=672815e4637d5, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609614, encodeId=bff316096147b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361775, encodeId=2a40361e7527, content=我们的病人严重血脂异常的都查甲功, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Fri Mar 01 11:01:13 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-02 pcw111
  3. [GetPortalCommentsPageByObjectIdResponse(id=1341321, encodeId=316d13413210a, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574637, encodeId=672815e4637d5, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609614, encodeId=bff316096147b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361775, encodeId=2a40361e7527, content=我们的病人严重血脂异常的都查甲功, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Fri Mar 01 11:01:13 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1341321, encodeId=316d13413210a, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574637, encodeId=672815e4637d5, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609614, encodeId=bff316096147b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 14:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361775, encodeId=2a40361e7527, content=我们的病人严重血脂异常的都查甲功, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Fri Mar 01 11:01:13 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-01 topnew

    我们的病人严重血脂异常的都查甲功

    0

相关资讯

Semin Arthritis Rheu:与高脂血症比较,大血管血管炎患者的血管钙化

与HLD相比,LVV中冠脉钙化的患病率较低,但LVV中整个大动脉的总血管钙化数量较多。

周仲瑛:治疗高血压、高脂血症对药经验介绍

高血压高脂血症常以头痛昏蒙、面赤升火为主症,属中医眩晕、头痛等范畴。其病机责之肾之精气不足、肝经气火上逆。诚如华岫云所说“精血亏耗,水不涵木,木少滋荣,故肝阳偏亢,内风时起”。肾精亏虚,可致肝风内动,血压升高,而肾气不足,蒸化无力,脾气失于输运,精化为浊,痰浊入血,又可导致血脂升高。

JACC:CVD一级预防:可通过管理糖尿病、高脂血症和高血压而实现?

因为高血压、糖尿病、高脂血症等问题,血管会经历“沉积-钙化-狭窄-破裂/闭塞”这样一个病变过程后,最终走向的结局就是我们所熟悉的心脑血管急性事件。2017年发表在《J Am Coll Cardiol》上的一项摘要,对冠心病的一级预防可通过管理糖尿病、高脂血症和高血压而实现进行了描述。

降脂治疗中的12个常见问题答疑

针对关于降脂治疗的一些常见问题,统一回答如下。

J Clin Lipidol:高脂血症患者预防CVD风险 辅酶Q10成潜在候选

2018年3月,发表在《J Clin Lipidol》的一项由中国科学家进行的项随机、双盲、安慰剂-对照试验,考察了24周辅酶Q10(CoQ10)对高脂血症患者血脂、血糖水平及心血管疾病(CVD)风险的影响。

J Clin Gastroenterol:高脂血症和非酒精性脂肪性肝炎对无肝硬化的肝癌发展的促进作用

肝细胞癌(HCC)占原发性肝脏恶性肿瘤的90%。 除慢性乙型肝炎(CHB)以外,慢性肝病的其他病因学需要在进展为HCC之前发展为肝硬化。已经有病例报告报导了在丙型肝炎和非酒精性脂肪性肝炎的非肝硬化患者中的HCC发生情况。